Table 3.
Recent clinical studies on immunotherapy.
| Year | Phase | Treatment | N | Patients | Clinical Significance | Ref. |
|---|---|---|---|---|---|---|
| 2016 | II | Standard therapy with or without immunotherapy using autologous lymphocytes, TL-pulsed DCs, with or without IL-7 | 43 | High-risk pediatric sarcomas: EWS (24), RMS (11), and others (8) | T-cell responses toTL: 62% Five-year OS: 73% in patients with T cell response and 37% in patients without T cell response |
[89] |
| 2015 | I/II | Decitabine followed by DC pulsed with MAGE-A1, MAGE-A3 and NY-ESO-1 peptides | 10 | NB (8), EWS (1), and RMS (1) | CR: 10%, SD 20%, PD 70% | [90] |
| 2015 | I/II | HER2-specific CAR T cells | 19 | HER2-positive tumors: Osteosarcoma (16), PNET (1), EWS (1), and DSRCT (1) | SD 24% | [91] |
TL, tumor lysate; DC, dendritic cell, IL, interleukin; MAGE, melanoma-associated gene; NY-ESO-1, New York esophageal squamous cell carcinoma-1; HER2, human epidermal growth factor receptor 2; CAR, chimeric antigen receptor; EWS, Ewing’s sarcoma; RMS, rhabdomyosarcoma; NB, neuroblastoma; PNET, primitive neuroectodermal tumor; DSRCT, desmoplastic small round cell tumor; TL, tumor lysate; OS, overall survival; CR, complete response; SD, stable disease; PD, progressive disease.